GI
APLS

GAMMA Investing’s Apellis Pharmaceuticals APLS Stock Holding History

GAMMA Investing’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-796
Closed -$32K – 4145
2026
Q1 		$32K Buy
796
+317
+66% +$6.83K ﹤0.01% 2461
2025
Q4 		$12K Buy
479
+249
+108% +$5.84K ﹤0.01% 2889
2025
Q3 		$5.21K Buy
230
+152
+195% +$3.54K ﹤0.01% 3162
2025
Q2 		$1.35K Sell
78
-390
-83% -$7.22K ﹤0.01% 3476
2025
Q1 		$10.2K Sell
468
-72
-13% -$1.99K ﹤0.01% 2732
2024
Q4 		$17.2K Buy
540
+137
+34% +$4.12K ﹤0.01% 2344
2024
Q3 		$11.6K Buy
403
+250
+163% +$9.26K ﹤0.01% 2387
2024
Q2 		$5.87K Sell
153
-81
-35% -$3.67K ﹤0.01% 2505
2024
Q1 		$13.8K Buy
234
+119
+103% +$7.59K ﹤0.01% 1877
2023
Q4 		$7.28K Buy
+115
New +$5.83K ﹤0.01% 2062

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

GAMMA Investing's APLS Position: Q2 2026 in Review

GAMMA Investing sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 796 shares — an estimated $32K sold.

GAMMA Investing first reported a position in APLS in Q4 2023 and held it in 10 quarters. The position peaked at $32K in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • GAMMA Investing reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • GAMMA Investing sold 796 Apellis Pharmaceuticals shares in Q2 2026, an estimated $32K.
  • GAMMA Investing first reported a position in Apellis Pharmaceuticals in Q4 2023 and held it in 10 quarters.
  • GAMMA Investing's Apellis Pharmaceuticals position peaked at $32K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.